Work

SOHO-02: Phase III trial of BAY 2927088 in patients with locally advanced or metastatic NSCLC with HER2 -activating mutations.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps8648

Authors: Xiuning Le, Koichi Goto, Shun Lu, Jan Christoph Brase, Judith Xu, Su-Fen Pu, Izabela Przybytniak, Lidia Mongay Soler, Edward B. Garon, Antonio Passaro

Institutions: The University of Texas MD Anderson Cancer Center, National Cancer Center Hospital East, Shanghai Jiao Tong University, Bayer (Switzerland), Bayer (United States), Bayer (United Kingdom), University of California, Los Angeles, European Institute of Oncology

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Bayer

OpenAlex ID: W4410804515

Cites:

Cited by: 4

Related to: 10